In 2001, The U.S. Food and Drug Administration (FDA) approved a medicine called alemtuzumab to help treat B-cell chronic lymphocytic leukemia, a sort of cancer. In 2014, the identical drug was approved by the FDA for treating multiple sclerosis (MS).
Sanofi Genzyme shortly released a version of the drug for MS patients under the brand name Lemtrada. Since Lemtrada’s launch, the FDA has identified at least 13 instances of strokes and arterial tears connected to its use.
Image Source: Google
At Ferrer, Poirot & Wansbrough, our national drug injury lawyers are here to fight for individuals that suffered arterial dissection, stroke, or arterial tears because of receiving Lemtrada. In the event you or your loved one suffered either of these side effects during or after Lemtrada remedies then you can consult lemtrada stroke lawyers.
FDA Issues Black Box Warning for Lemtrada
According to The FDA, Lemtrada can increase the risk of arterial dissection, which may result in strokes and arterial tearing from the head and neck regions of patients with multiple sclerosis. These complications most often occur soon after receiving the medication usually within a day and they may result in permanent disability or even death.
On November 29, 2018, the FDA announced the addition of a black box warning to Lemtrada packaging to increase awareness of the risk of stroke or arterial dissection after beginning treatment. The black box warning is the FDA’s strictest warning and is only issued when a significant health hazard is connected to the use of a drug.
Image Source: Google
Symptoms of Stroke and Artery Tears Connected to Lemtrada
An Assortment of Symptoms may indicate arterial dissection, which can lead to stroke and arterial tearing. Indications of Severe Lemtrada complications include abrupt:
Numbness or Weakness in the face, arms, or legs–especially on one side of their body
Confusion, Difficulty speaking, or difficulty understanding speech
Problems With walking, dizziness, or balance
Severe headache or neck pain
These Symptoms most often appear within 1-3 days of beginning Lemtrada and require emergency treatment as soon as possible.